期刊文献+

噻唑烷二酮类药物对2型糖尿病患者体重、水肿及心功能的影响 被引量:1

下载PDF
导出
摘要 随着对2型糖尿病的深入研究,噻唑烷二酮类药物在糖尿病的防治中占有重要地位。噻唑烷二酮类药物匹格列酮和罗格列酮的大量应用,部分患者可能出现体重增加、水肿甚至心功能不全,在一定程度上限制了其临床应用。而匹格列酮和罗格列酮用于治疗2型糖尿病患者,出现体重增加,可通过低热量、低盐饮食,适量体力锻炼而避免。出现水肿,轻的患者停用后消失,重的患者需加用利尿剂治疗。至于心力衰竭,认为NYHA心功分级为Ⅰ级和Ⅱ级的心力衰竭患者,在严密监测下仍可慎用,Ⅲ级和Ⅳ级心力衰竭患者不用。
出处 《四川医学》 CAS 2007年第3期262-264,共3页 Sichuan Medical Journal
  • 相关文献

参考文献18

  • 1Fernando Ovalle MD,FACE David S H Bell,MB FACE.Fffect of rOsiglitazone versus insulin on the pancreatic-cell function of subjects with type 2diabetes[N].Diabetes Care,2004,27:2585~2589
  • 2Dormandy JA,Charbonnel B,Eckland DJ,et al.Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO active Study (PROspective pioglitazone Clinical Trial In macro Vascular Events):a randomised controlled trial[J].Lancet,2005,366 (9493):1279~1289
  • 3The DREAM Trail investgator.Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:a randomized controlled trail[J].Lancet,2006,368:1096~1105
  • 4文迪雅Ⅳ期临床研究协作组.罗格列酮治疗2型糖尿病的临床观察[J].中华内科杂志,2003,42(9):636-639. 被引量:26
  • 5Hussein Z,Wentworth JM,Nankervis AJ,et al.Effectiveness and side effects of thiazolidinediones for type 2 diabetes:real-life experience from a tertiary hospital[J].Med J Aust,2004,181 (10):536~539
  • 6YouFei Guan,Chuanming Hao,Dae Ryong Cha,et al.Thiazolidinediones expand body fluid volume through PPAR γ stimulation of EnaC-mediated renal salt absorption[J].Nature medicine,2005,11(8):861~868
  • 7Zhang H,Zhang A,Kohan DE,et al.Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedioneinduced fluid retention[J].Proc Natl Acad Sci U S A,2005,102(26):9406~9411
  • 8Fonsece V.Effect of thiazolidinediones on body weight in patients with diabetes mellitus[J].Am J Med,2003,115(8):42~48
  • 9Berlie HD,Kalus JS,Jaber LA.Thiazolidinediones and the risk of edema:A meta-analysis[J].Diabetes Res Clin Pract,2006,17
  • 10Mudaliar S,Change AR,Henry RR.Thiazolidinediones,peripheral edema,and type 2 diabetes:incidence,pathophysiology,and clinical implications[J].Endocr,Pract,2003,9:406~416

二级参考文献8

共引文献28

同被引文献15

  • 1曾维新,颜文盛.吡格列酮治疗糖耐量异常临床研究[J].实用药物与临床,2005,8(4):29-30. 被引量:1
  • 2杨兆军,颜树峰,邢小燕,王宣,李光伟.盐酸吡格列酮对磺脲类和双胍类药物联合治疗失效的2型糖尿病患者的疗效观察[J].中国综合临床,2005,21(12):1099-1101. 被引量:9
  • 3张长春.吡格列酮联合胰岛素治疗2型糖尿病的临床观察[J].实用药物与临床,2006,9(4):227-228. 被引量:2
  • 4Carlsson A,Sundkvist G,Groop L. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LA-DA)[J].Journal of Clinical Endocrinology and Metabolism,2000,(01):76-80.
  • 5Delerive P,Fruchart JC,Staels B. peroxisome proliferator-activated receptors in inflammation control[J].Journal of Endocrinology,2001,(03):453-459.doi:10.1677/joe.0.1690453.
  • 6Pozzilli P,Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult):definition,characterization,and potential prevention[J].Diabetes Care,2001,(08):1460-1467.doi:10.2337/diacare.24.8.1460.
  • 7廖二元;莫朝晖.内分泌学[M]北京:人民卫生出版社,20071428-1429.
  • 8Alvarsson M,Sundkvist G,Lager I. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control inrecently diagnosed type2 diabetic patients[J].Diabetes Care,2003,(08):2231-2237.doi:10.2337/diacare.26.8.2231.
  • 9Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus[J].New England Journal of Medicine,2002,(22):1685-1691.
  • 10Skyler JS,Kriseher JP,Wolfsdorf J. Effects of oral insulin in relatives of patients with type 1 diabetes:the Diabetes Prevention Trial-Type 1[J].Diabetes Care,2005,(05):1068-1076.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部